Quantcast
Home » News
Home » News

Initial public offerings scheduled to debut next week

Published June 13, 2014 11:28 am
This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

New York • The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT (www.renaissancecapital.com) and SEC filings.

Week of June 16:

Ardelyx Inc. - Fremont, Calif., 3.6 million shares, priced $13 to $15, managed by Citigroup and Leerink Partners. Proposed Nasdaq symbol ARDX. Business: Biotech developing small molecule treatments for kidney and gastrointestinal diseases.



Century Communities Inc. - Greenwood Village, Colo., 4.5 million shares, priced $23 to $26, managed by FBR Capital Markets, J.P. Morgan, and Deutsche Bank. Proposed NYSE symbol CCS. Business: Single-family homebuilder primarily in Colorado, as well as Texas and Nevada.

Eclipse Resources Corp. - State College, Pa., 30.3 million shares, priced $27 to $30, managed by Citigroup, Goldman Sachs, and Morgan Stanley. Proposed NYSE symbol ECR. Business: Oil and natural gas E&P operating in the Appalachian Basin.

Foresight Energy LP - St. Louis, Mo., 17.5 million shares, priced $19 to $21, managed by Barclays, Citigroup, and Morgan Stanley. Proposed NYSE symbol FELP. Business: Spinoff of Foresight Reserves with 3 billion tons of coal reserves in the Illinois basin.

Kite Pharma Inc. - Santa Monica, Calif., 6 million shares, priced $12 to $14, managed by Jefferies, Credit Suisse, and Cowen & Co. Proposed Nasdaq symbol KITE. Business: Clinical stage biotech developing an immunotherapy cancer treatment.

Markit Ltd. - London, U.K., 45.7 million shares, priced 23 to $25, managed by BofA Merrill Lynch, Barclays, and Citigroup. Proposed Nasdaq symbol MRKT. Business: Largest provider of bond information and derivatives trade processing.

Microlin Bio Inc. - New York, 2.7 million shares, priced $10 to $12, managed by Brean Capital and Summer Street Research. Proposed Nasdaq symbol MCLB. Business: Development stage diagnostic and therapeutics company focusing on microRNA and its role in oncology. Issue was previously postponed.

Parnell Pharmaceuticals Holdings Ltd. - Alexandria, Australia, 3.6 million ordinary shares, priced $17 to $19, managed by Jefferies and Piper Jaffray. Proposed Nasdaq symbol PARN. Business: Provides drugs and health software for production and companion animals.

Syndax Pharmaceuticals Inc. - Waltham, Mass., 4.3 million shares, priced $13 to $15, managed by Deutsche Bank and Jefferies. Proposed Nasdaq symbol SNDX. Business: Late-stage biotech developing a novel therapy for treatment-resistant breast cancer.

Viper Energy Partners LP - Midland, Texas, 5 million common units, priced $19 to $21, managed by Barclays, Credit Suisse, and Wells Fargo. Proposed Nasdaq symbol VNOM. Business: Oil and gas E&P in the Permian Basin spun out of Diamondback Energy.

Zafgen Inc. - Cambridge, Mass., 5 million shares, priced $14 to $16, managed by Leerink Partners and Cowen & Co. Proposed Nasdaq symbol ZFGN. Business: Clinical-stage biotech developing treatments for severe obesity and hunger-related disorders.

ZS Pharma Inc. - Coppell, Texas, 5 million shares, priced $15 to $17, managed by J.P. Morgan and Credit Suisse. Proposed Nasdaq symbol ZSPH. Business: Late-stage biotech developing a treatment for excess potassium (hyperkalemia).

 

 

 

USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus